Erin D. Michos, MD, MHS, shares a preview of the late-breaking clinical trials that she is looking forward to at the American College of Cardiology 2022 Scientific Session and Expo in Washington, DC, on April 2-4. First, Dr Michos anticipates the results of the phase 1 APOLLO trial that will be presented by Steven Nissen, MD, which measures the efficacy of a short-interfering RNA targeting lipoprotein (a).
Next, Dr Michos looks at the forthcoming PACMAN-AMI trial, presented by Lorenz Raber, MD, which looks at coronary plaque composition change with alirocumab treatment and its effects on a statin.
Last, Dr Michos awaits the results of a secondary analysis, which she participated in, from the pooled FIDELITY study results of the large phase 3 trials FIDELIO-DKD and FIGARO-DKD, which investigated finerenone, a novel RNA, in patients with type 2 diabetes and chronic kidney disease.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: A Look Ahead to ACC 2022: Late-Breaking Clinical Trials in Lipid Management - Medscape - Apr 04, 2022.